title: Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
abstract: BACKGROUND
  Few studies have investigated the factors related to improvement and maintenance of glycemic control with sitagliptin in Type 2 diabetes (T2D) patients.
  
  
  OBJECTIVE
  To identify factors contributing to reaching and maintaining glycated hemoglobin (HbA1c) <7% with sitagliptin in Japanese T2D patients.
  
  
  METHODS
  This study included 1327 patients who were: taking sitagliptin as monotherapy; switched to sitagliptin; or taking sitagliptin in combination therapy. At baseline and 1, 3, 6, and 12 months after starting sitagliptin, weight, body mass index (BMI), HbA1c, fasting plasma glucose (FPG), and post-prandial plasma glucose (PPG) were measured. The subjects were divided into a group that achieved HbA1c<7% at 12 months, a poor control group (HbA1c≥8% at 12 months), and a discontinued group. Multiple regression analysis was performed to identify factors contributing to long-term control and maintenance with sitagliptin treatment.
  
  
  RESULTS
  HbA1c decreased significantly from 8.0% at baseline to 7.3%, but weight was unchanged. FPG and PPG improved significantly. The HbA1c<7% group had a significantly higher age and a signifi cant ly lower BMI at baseline than the HbA1c≥8% group and the discontinued group. On multivariate regression analysis, baseline HbA1c, baseline BMI, and Δbody weight after 12 months were significantly related to HbA1c reduction. The most common adverse event was hypoglycemia, and the most common adverse event responsible for discontinuation was constipation.
  
  
  CONCLUSIONS
  HbA1c<7.0% was achieved in 31% of T2D patients who had poor control with conventional treatment. Weight management is important for maintaining good long-term control with sitagliptin.
authors: The Study Group of the Diabetes Committee, Kanagawa Physicians Association, Yokohama-city, Japan. hec@asahi-net.email.ne.jp.
authors: H
authors: H
authors: Maeda
authors: A
authors: A
authors: Kubota
authors: A
authors: A
authors: Kanamori
authors: Y
authors: Y
authors: Tanaka
authors: Y
authors: Y
authors: Terauchi
authors: I
authors: I
authors: Matsuba
mesh_terms: D000368:Aged; D044466:Asian People; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D011719:Pyrazines / Q000009:adverse effects*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles
references: Diabetes Care. 2011 Jan;34 Suppl 1:S11-61
references: 21193625
references: Diabetes Res Clin Pract. 2012 Jan;95(1):e20-2
references: 22055835
references: J Clin Endocrinol Metab. 1964 Oct;24:1076-82
references: 14228531
references: Diabetes Obes Metab. 2010 Jul;12(7):613-22
references: 20590736
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: Diabetes. 2008 May;57(5):1340-8
references: 18162504
references: Eur J Epidemiol. 1999 Jul;15(6):507-15
references: 10485342
references: J Diabetes Investig. 2012 Oct 18;3(5):464-7
references: 24843607
references: Diabetes. 2008 Mar;57(3):678-87
references: 18057091
references: J Diabetes Investig. 2012 Dec 20;3(6):503-9
references: 24843615
references: Diabetes Obes Metab. 2011 Jul;13(7):594-603
references: 21320267
references: Diabetologia. 2009 Feb;52(2):199-207
references: 19037628
references: J Clin Med Res. 2012 Oct;4(5):309-13
references: 23024732
references: J Clin Endocrinol Metab. 1965 Oct;25(10):1317-24
references: 5320560
references: Lancet. 2006 Nov 11;368(9548):1696-705
references: 17098089
references: Endocr J. 2010;57(6):499-507
references: 20208396
references: Diabetes Res Clin Pract. 1999 May;44(2):129-36
references: 10414932
references: Diabetes Res Clin Pract. 2008 Feb;79(2):291-8
references: 17933414
references: Diabetologia. 2011 Jan;54(1):10-8
references: 20871975
references: Endocr J. 2012;59(3):197-204
references: 22156327